Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial

Gerd Plewig; William J. Cunliffe; Natascha Binder; Kornelia Höschen

doi:10.1016/j.contraception.2009.02.016

Efficacy of an oral contraceptive containing EE 0.03 mg and CMA 2 mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial

Contraception ◽

10.1016/j.contraception.2009.02.016 ◽

2009 ◽

Vol 80 (1) ◽

pp. 25-33 ◽

Cited By ~ 27

Author(s):

Gerd Plewig ◽

William J. Cunliffe ◽

Natascha Binder ◽

Kornelia Höschen

Keyword(s):

Oral Contraceptive ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Efficacy of an oral contraceptive containing EE 0.03mg and CMA 2mg (Belara®) in moderate acne resolution: a randomized, double-blind, placebo-controlled Phase III trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(09)79474-2 ◽

2010 ◽

Vol 2010 ◽

pp. 218-219

Author(s):

D. Thiboutot

Keyword(s):

Oral Contraceptive ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1146988.604098 ◽

2009 ◽

Author(s):

Frank Pessler

Keyword(s):

Juvenile Idiopathic Arthritis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Withdrawal Phase ◽

Systemic Onset

Download Full-text

Faculty Opinions recommendation of Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717996902.793477633 ◽

2013 ◽

Author(s):

Virginia Kraus

Keyword(s):

Hip Pain ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

Arthritis & Rheumatism ◽

10.1002/art.22025 ◽

2006 ◽

Vol 54 (9) ◽

pp. 2793-2806 ◽

Cited By ~ 1041

Author(s):

Stanley B. Cohen ◽

Paul Emery ◽

Maria W. Greenwald ◽

Maxime Dougados ◽

Richard A. Furie ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis ◽

Phase Iii ◽

Primary Efficacy ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Factor Therapy ◽

Necrosis Factor

Download Full-text

RESPONSE: Re: Double-Blind, Placebo-Controlled, Randomized Phase III Trial of Darbepoetin Alfa in Lung Cancer Patients Receiving Chemotherapy

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/95.10.762 ◽

2003 ◽

Vol 95 (10) ◽

pp. 762-763

Author(s):

J. F. Vansteenkiste ◽

A. B. Colowick

Keyword(s):

Lung Cancer ◽

Cancer Patients ◽

Darbepoetin Alfa ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Lung Cancer Patients

Download Full-text

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

Yearbook of Oncology ◽

10.1016/j.yonc.2011.08.001 ◽

2011 ◽

Vol 2011 ◽

pp. 33-34

Author(s):

J.T. Thigpen

Keyword(s):

Growth Factor Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Epidermal Growth ◽

Locally Recurrent ◽

First Line Treatment

Download Full-text

PRE-surgical Metformin In Uterine Malignancy (PREMIUM): a Multi-Center, Randomized Double-Blind, Placebo-Controlled Phase III Trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-18-3339 ◽

2018 ◽

Vol 25 (8) ◽

pp. 2424-2432 ◽

Cited By ~ 16

Author(s):

Sarah J. Kitson ◽

Zoe Maskell ◽

Vanitha N. Sivalingam ◽

Jennifer L. Allen ◽

Saad Ali ◽

...

Keyword(s):

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2261 ◽

2020 ◽

Vol 31 ◽

pp. S1161-S1162 ◽

Cited By ~ 1

Author(s):

K.N. Moore ◽

M. Bookman ◽

J. Sehouli ◽

A. Miller ◽

C. Anderson ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Iii ◽

Stage Iii ◽

Newly Diagnosed ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2070 ◽

2020 ◽

Vol 31 ◽

pp. S606

Author(s):

D.M. Somford ◽

S. Daneshmand ◽

P. Grivas ◽

S. Sridhar ◽

S. Gupta ◽

...

Keyword(s):

Adjuvant Therapy ◽

Urothelial Carcinoma ◽

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo

Download Full-text

The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial

Journal of Allergy and Clinical Immunology ◽

10.1016/j.jaci.2018.12.1001 ◽

2019 ◽

Vol 143 (3) ◽

pp. 1058-1066.e6 ◽

Cited By ~ 21

Author(s):

Tilo Biedermann ◽

Piotr Kuna ◽

Petr Panzner ◽

Erkka Valovirta ◽

Morgan Andersson ◽

...

Keyword(s):

Phase Iii ◽

Double Blind ◽

Phase Iii Trial ◽

Double Blind Placebo ◽

Highly Effective

Download Full-text